WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999040914) BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/040914    International Application No.:    PCT/GB1999/000335
Publication Date: 19.08.1999 International Filing Date: 02.02.1999
Chapter 2 Demand Filed:    23.08.1999    
IPC:
C07D 487/04 (2006.01), C07D 491/04 (2006.01), C07D 495/04 (2006.01), C07D 513/04 (2006.01)
Applicants: ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate London W1Y 6LN (GB) (For All Designated States Except US).
BARKER, Andrew, John [GB/GB]; (GB) (For US Only).
KETTLE, Jason, Grant [GB/GB]; (GB) (For US Only).
FAULL, Alan, Wellington [GB/GB]; (GB) (For US Only)
Inventors: BARKER, Andrew, John; (GB).
KETTLE, Jason, Grant; (GB).
FAULL, Alan, Wellington; (GB)
Agent: DENERLEY, Paul, Millington; Global Intellectual Property AstraZeneca UK Limited Mereside, Alderley Park Macclesfield Cheshire SK10 4TG (GB)
Priority Data:
9803228.7 17.02.1998 GB
Title (EN) BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS
(FR) DERIVES BICYCLIQUES DU PYRROLE, INHIBITEURS DE LA MCP-1
Abstract: front page image
(EN)A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or esters of amides thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B together form an optionally substituted 5-membered aromatic ring which includes at least one heteroatom; X is CH¿2? or SO¿2?; R?1¿ is an optionally substituted aryl or heteroaryl ring; R?2¿ is selected from a range of organic groups including carboxy, and R?3¿ is hydrogen, or a range of organic groups; in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and these form a further aspect of the invention.
(FR)L'invention porte sur une préparation pharmaceutique comportant un composé de formule (I) ou l'un de ses sels ou esters d'amide pharmacocompatible agissant comme inhibiteur de la protéine dite MCP-1 (protéine chimiotactique vis à vis des monocytes N°1). Dans la formule: A et B forment ensemble un cycle aromatique facultativement substitué à 5 éléments comportant au moins un hétéroatome; X est CH¿2? ou SO¿2?; R?1¿ est un cycle aryle ou hétéroaryle facultativement substitué; R?2¿ est choisi parmi une série de groupes organiques dont carboxy, R?3¿ est H, ou une série de groupes organiques. L'ensemble est associé à un excipient pharmacocompatible. Certains composés de formule (I) sont nouveaux et ces formes font partie de l'invention.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)